Bicycle Therapeutics: First patient dosed in Phase I/II trial of BT7480 07:27 BCYC
Builders FirstSource raises FY21 revenue view to $19.3B-$19.8B from $18B-19B 07:16 BLDR FY21 revenue consensus $18.5B. Adjusted EBITDA to be in a range of $2.85B-$2.95B, previous guidance $2.2B-$2.4B. Expected BMC merger integration realized cost savings of $90M-$110M, previous guidance $80M-$100M. Free cash flow in the range of $1.8B-$2.0B, previous guidance $1.4B-$1.6B.
Steven Madden price target raised to $55 from $49 at Citi 06:47 SHOO Citi analyst Paul Lejuez raised the firm's price target on Steven Madden to $55 from $49 and keeps a Neutral rating on the shares following the "solid" Q3 results. The Q4 guidance suggests a big acceleration in sales as wholesale orders finally catch up with strong sell through that Steven Madden has seen at retail all year, Lejuez tells investors in a research note.
I told my sad story about throwing away my weed to my guy hoping he would cut me a break...
He just told be a better story...
Builders FirstSource raises FY21 revenue view to $19.3B-$19.8B from $18B-19B 07:16 BLDR FY21 revenue consensus $18.5B. Adjusted EBITDA to be in a range of $2.85B-$2.95B, previous guidance $2.2B-$2.4B. Expected BMC merger integration realized cost savings of $90M-$110M, previous guidance $80M-$100M. Free cash flow in the range of $1.8B-$2.0B, previous guidance $1.4B-$1.6B.
Steven Madden price target raised to $55 from $49 at Citi 06:47 SHOO Citi analyst Paul Lejuez raised the firm's price target on Steven Madden to $55 from $49 and keeps a Neutral rating on the shares following the "solid" Q3 results. The Q4 guidance suggests a big acceleration in sales as wholesale orders finally catch up with strong sell through that Steven Madden has seen at retail all year, Lejuez tells investors in a research note.
I told my sad story about throwing away my weed to my guy hoping he would cut me a break...
He just told be a better story...
